FIA
CSBR icon

FNY Investment Advisers’s Champions Oncology CSBR Stock Holding History

FNY Investment Advisers’s Portfolio CSBR Stock Details CSBR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-672
Closed -$5K – 928
2019
Q2 		$5K Buy
+672
New +$5.89K ﹤0.01% 687

Other funds holding CSBR

BPI
Battery Partners IX Boston, Massachusetts $22.4M AUM 27.71% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CCM
Cadence Capital Management Boston, Massachusetts $415M AUM 11.01% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TAM
Tocqueville Asset Management New York $6.74B AUM 32.29% 1-Year Est. Return

FNY Investment Advisers's CSBR Position: Q3 2019 in Review

FNY Investment Advisers sold out of Champions Oncology (CSBR) in Q3 2019, closing a stake of 672 shares — an estimated $5K sold.

FNY Investment Advisers first reported a position in CSBR in Q2 2019 and held it in 1 quarter. The position peaked at $5K in Q2 2019. 33 funds tracked by Wall St. Rank hold CSBR as of Q3 2019.

  • FNY Investment Advisers reported no remaining Champions Oncology position as of Q3 2019 after selling out during the quarter.
  • FNY Investment Advisers sold 672 Champions Oncology shares in Q3 2019, an estimated $5K.
  • FNY Investment Advisers first reported a position in Champions Oncology in Q2 2019 and held it in 1 quarter.
  • FNY Investment Advisers's Champions Oncology position peaked at $5K in Q2 2019.
  • 33 funds tracked by Wall St. Rank held Champions Oncology as of Q3 2019.

Based on FNY Investment Advisers's 13F filing for Q3 2019, filed 25 Oct 2019.